Multiple sclerosis: pharmacogenomics and personalised drug treatment

被引：0
作者：
V. Annibali
G. Ristori
S. Cannoni
S. Romano
A. Visconti
A. Ghazaryan
L. Figà Talamanca
M. Salvetti
R. Mechelli
机构：
[1] Ospedale S. Andrea,Department of Neurology and Centro Neurologico Terapia Sperimentale (CENTERS)
[2] University of Rome “La Sapienza”,undefined
来源：
Neurological Sciences | 2006年 / 27卷
关键词：
Pharmacogenomics; Multiple sclerosis; Therapy; Microarrays;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Multiple sclerosis (MS) is a disorder of the central nervous system with an inflammatory and a neurodegenerative component. We do not yet have a definitive therapy for MS. Attempts to develop new treatments are long and costly and should be paralleled by studies aimed at increasing the therapeutic index of the existing treatments, interferon β and glatiramer acetate. Pharmacogenetics and pharmacogenomics may be of use in this respect though their application may not be straightforward, particularly in MS.
引用
收藏
页码：s347 / s349
相关论文
共 50 条
  • [21] Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research
    Grossman, Iris
    Knappertz, Volker
    Laifenfeld, Daphna
    Ross, Colin
    Zeskind, Ben
    Kolitz, Sarah
    Ladkani, David
    Hayardeny, Liat
    Loupe, Pippa
    Laufer, Ralph
    Hayden, Michael
    PROGRESS IN NEUROBIOLOGY, 2017, 152 : 114 - 130
  • [22] Advancing drug delivery systems for the treatment of multiple sclerosis
    Tabansky, Inna
    Messina, Mark D.
    Bangeranye, Catherine
    Goldstein, Jeffrey
    Blitz-Shabbir, Karen M.
    Machado, Suly
    Jeganathan, Venkatesh
    Wright, Paul
    Najjar, Souhel
    Cao, Yonghao
    Sands, Warren
    Keskin, Derin B.
    Stern, Joel N. H.
    IMMUNOLOGIC RESEARCH, 2015, 63 (1-3) : 58 - 69
  • [23] Advancing drug delivery systems for the treatment of multiple sclerosis
    Inna Tabansky
    Mark D. Messina
    Catherine Bangeranye
    Jeffrey Goldstein
    Karen M. Blitz-Shabbir
    Suly Machado
    Venkatesh Jeganathan
    Paul Wright
    Souhel Najjar
    Yonghao Cao
    Warren Sands
    Derin B. Keskin
    Joel N. H. Stern
    Immunologic Research, 2015, 63 : 58 - 69
  • [24] Multiple Sclerosis: Pathogenesis and Treatment
    Loma, Ingrid
    Heyman, Rock
    CURRENT NEUROPHARMACOLOGY, 2011, 9 (03) : 409 - 416
  • [25] Current treatment of multiple sclerosis
    Gout, O.
    Bensa, C.
    Assouad, R.
    REVUE DE MEDECINE INTERNE, 2010, 31 (08): : 575 - 580
  • [26] An Investigation into the Desire for Personalised Information Provision by People with Multiple Sclerosis
    Qutaishat, Fadi T.
    Probets, Steve
    Hepworth, Mark
    BUSINESS TRANSFORMATION THROUGH INNOVATION AND KNOWLEDGE MANAGEMENT: AN ACADEMIC PERSPECTIVE, VOLS 1-2, 2010, : 458 - +
  • [27] Laquinimod is an oral drug with a marked neuroprotective effect for pathogenetic treatment of multiple sclerosis (review)
    Boyko, A. N.
    Gusev, E. I.
    ZHURNAL NEVROLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2013, 113 (02) : 93 - 99
  • [28] Natalizumab Treatment in Multiple Sclerosis
    Kurtuncu, Murat
    NOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY, 2011, 48 : 56 - 60
  • [29] Treatment of multiple sclerosis fatigue with the synthetic psychoactive drug modafinil
    Cocco, Eleonora
    Fadda, Paola
    EXPERIMENTAL NEUROLOGY, 2022, 347
  • [30] Liposome-Assisted Drug Delivery in the Treatment of Multiple Sclerosis
    Greco, Giuliana
    Sarpietro, Maria Grazia
    MOLECULES, 2024, 29 (19):
12345